We report an unusual case of primary cutaneous CD30+ anaplastic large cell lymphoma in a 58-year-old man who presented with disseminated hyperpigmented patches, papules, and nodules. Our case is also unusual in that the patient did not respond to an intensive chemotherapy regimen in contrast to previously reported cases of primary cutaneous CD30+ anaplastic large cell lymphoma.
Drug Therapy ; Humans ; Lymphoma, Large-Cell, Anaplastic* ; Middle Aged

Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is rare among skin malignancies. C-ALCL usually manifests as reddish or violet nodules. Surgical excision or radiation therapy is generally considered as first-line therapy, but a clinically aggressive disease may require multiagent chemotherapy. Establishing a proper diagnosis of C-ALCL is challenging but should be made to avoid inappropriate treatment and its consequences. The authors report a case of medically resolved C-ALCL in an 81-year-old man presented with well-defined nodular lesions on the forehead.
Aged, 80 and over ; Diagnosis ; Drug Therapy ; Forehead ; Humans ; Lymphoma, Large-Cell, Anaplastic ; Lymphoma, Primary Cutaneous Anaplastic Large Cell ; Lymphoma, T-Cell ; Skin ; Viola

Humans ; Lymphoma, Large-Cell, Anaplastic ; diagnosis ; enzymology ; therapy ; Receptor Protein-Tyrosine Kinases

OBJECTIVETo analyze the clinical features and prognostic factors of children's anaplastic large cell lymphoma (ALCL), summarize the therapeutic effect and toxicities.

METHODA total of 38 ALCL patients admitted to Beijing Children's Hospital from Jan. 2003 to Apr. 2010 were treated with BCH-ALCL-2003 regimen (modified from HK-ALCL-2000).

RESULTThirty-four cases were ALK(+), male:female ratio = 2.16:1. The median age was 9 years; 86.8% had B symptoms. 94.7% evolved to Stage III and IV on admission. The median follow-up duration was 48 months (12 to 99 months). Median event-free survival (EFS) time was 43 months. Thirty-four patients (89.5%) achieved a remission. The disease relapsed in 3 patients within 20 months after diagnosis. Estimated 4-year EFS was (81.2 ± 6.4)%, estimated 4-year overall survival (OS) rate was (86.4 ± 5.7)%. Univariate analysis indicated that the unfavorable prognostic factors included: more than 3 extra nodal involvement, hepatosplenomegaly (> 3 cm), elevated lactate dehydrogenase (LDH), stage IV, hemophagocytosis in bone marrow, and age < 3 years. The major toxicity was myelosuppression and mucositis. no chemotherapy related death occurred.

CONCLUSION(1) Childhood ALCL patients often have B symptoms and extranodal involvement. (2) In the study, therapeutic effects was good. The disease relapsed mostly within the first 2 years, maintenance therapy with vinblastine is necessary. (3) The regimen is safe to patients.

Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Lymphoma, Large-Cell, Anaplastic ; diagnosis ; therapy ; Male ; Prognosis ; Treatment Outcome

Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous CD30+ (anaplastic) large T cell lymphoma, lymphomatoid papulosis, and borderline cases. These represent a clinical and histologic continuum rather than a separate entity. We report a 39-year-old woman with the clinical features of lymphomatoid papulosis. Histology favored primary CD30+ anaplastic large cell lymphoma. Although she was treated with aggressive combination chemotherapy, the lesions recurred shortly after discontinuation of chemotherapy. She is now regularly followed up without any treatment.
Adult ; Drug Therapy ; Drug Therapy, Combination ; Female ; Humans ; Lymphoma, Large-Cell, Anaplastic ; Lymphoma, T-Cell ; Lymphomatoid Papulosis* ; Lymphoproliferative Disorders

Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare subtype of malignant non-Hodgkin lymphoma, in which 40% of the cases show spontaneous regression without aggressive treatment. Surgery and focal radiation therapy are the primary forms of treatment for this disease; however, if pcALCL is accompanied by multifocal skin lesions, chemotherapy is also common. The prognosis for pcALCL is generally excellent, with a 5-year survival rate of 85-100%. However, pcALCL with extensive limb disease typically has a poor prognosis. Here, we present a case of pcALCL with extensive limb disease that resulted in the patient's death, despite the use of aggressive chemotherapy.
Drug Therapy ; Extremities* ; Lymphoma ; Lymphoma, Non-Hodgkin ; Lymphoma, Primary Cutaneous Anaplastic Large Cell* ; Prognosis ; Skin ; Survival Rate

Two cases of CD30 positive ALCL is presented. A 27 year-old male patient presented with general lymphadenopathies, hepatosplenomegaly, splenic infarction, acute hepatitis, and hemopagocytic syndrome. The other 66 year-old female patient presented with general lymphadenopathies. Biopsy of the lymph node revealed proliferation of anaplastic pleomorphic tumor cells in the sinusoidal pattern. Immunohistochemical study revealed tumor cells were positive for LCA, T cell, and CD 30. All two cases were stage IIIA. Young patient was treat with 8 cycles of ProMACE-CytaBOM chemotherapy, and elderly patient was treated with 8 cycles of CHOP chemotherapy that resulted in complete remission with favorable clinical course.
Adult ; Aged ; Biopsy ; Drug Therapy ; Female ; Hepatitis ; Humans ; Lymph Nodes ; Lymphoma ; Lymphoma, Large-Cell, Anaplastic* ; Male ; Splenic Infarction

Endobronchial involvement in non-Hodgkin's lymphoma is rare. We experienced 36-year-old woman with endobronchial non-Hodgkin's lymphoma whose first presentation was breathless ness due to the total atelectasis of the left lung. The patient underwent fiberoptic bronchoscopy and the histologic finding with immunohistochemical staining confirmed CD30(+), EMA(+) anaplastic large cell lymphoma. Although the patient showed dramatic response to radiation therapy and combination chemotherapy, subsequently she died of disease progression.
Adult ; Bronchoscopy ; Disease Progression ; Drug Therapy, Combination ; Female ; Humans ; Lung ; Lymphoma, Large-Cell, Anaplastic ; Lymphoma, Non-Hodgkin* ; Pulmonary Atelectasis

We report a case of a 13-year-old girl who presented with a 2-month history of intermittent abdominal pain. Laboratory examination showed hepatitis and pancreatitis. Because of persistent vomiting, computed tomography (CT) was performed, which revealed a circumferential soft tissue density in the duodenal wall, causing partial obstruction. Supportive therapy failed. Repeat CT showed no significant change from the initial study. The patient underwent upper endoscopy, which revealed a mass in the second portion of the duodenum, which occluded most parts of the lumen. The histopathological finding was consistent with an anaplastic large cell lymphoma, a rare form of small bowel neoplasm. After the third course of chemotherapy, complete resolution of the mass was noted, and her symptoms were relieved.
Abdominal Pain ; Adolescent ; Drug Therapy ; Duodenum ; Endoscopy ; Female ; Hematoma ; Hepatitis ; Humans ; Lymphoma, Large-Cell, Anaplastic ; Pancreatitis ; Vomiting

Patients with lymphomatoid papulosis have an increased risk (approx. 5% to 20%) of developing a malignant lymphoma such as mycosis fungoides, anaplastic large cell lymphoma (ALCL) and Hodgkin's disease before, during, or after lymphomatoid papulosis occurs. However, it is very rare that lymphomatoid papulosis occurs after ALCL, especially in childhood. An 11-year-old boy who had been diagnosed with ALCL 3 years prior and treated with chemotherapy and peripheral blood stem cell transplantation developed multiple scaly papules on his trunk and both extremities. Histopathologic and immunohistochemical examination of the scaly papules revealed lymphomatoid papulosis. The patient was cured with narrow band UVB treatment and there has been no relapse in lesions 10 years later. We report a case of lymphomatoid papulosis following allogenic stem cell transplantation for ALCL.
Child* ; Drug Therapy ; Extremities ; Hodgkin Disease ; Humans ; Lymphoma ; Lymphoma, Large-Cell, Anaplastic* ; Lymphomatoid Papulosis* ; Male ; Mycosis Fungoides ; Peripheral Blood Stem Cell Transplantation ; Recurrence ; Stem Cell Transplantation